Oncology Pharma Inc: Breakthrough Cancer Research vs. Financial Instability
Oncology Pharma Inc’s cutting‑edge cancer therapies clash with a fragile financial outlook—stock plummeting to $0.02 amid a $417k market cap, raising concerns about future sustainability and biotech’s cost‑innovation dilemma.
2 minutes to read